A new treatment is effective for advanced HER2-low breast cancer
Treatment with trastuzumab deruxtecan, a combination of a targeted therapy with chemotherapy, increases progression-free survival of the disease and1
Treatment with trastuzumab deruxtecan, a combination of a targeted therapy with chemotherapy, increases progression-free survival of the disease and1
The new test, called HER2DX, analyzes RNA on 27 genes to predict survival outcomes and the likelihood that patients will respond to treatment.
A study conducted at Hospital Clínic analysed the genetic profile of more than 300 patients with solid tumours using a liquid biopsy blood test, resu1
On Thursday, 11 November, the Spanish Cancer Association (AECC) awarded the AECC 2021 Grants for Cancer Research at an event held at the organization1
Researchers from Hospital Clínic-IDIBAPS have shown for the first time that the benefit of chemotherapy in premenopausal patients with low-risk hormo1
IDIBAPS looks for talented professionals to meet the needs that appear periodically.
Enter